Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 2/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 3/20 | 0.31 |
| ▸ | CTSS | P25774 | 3/20 | 0.31 |
| ▸ | CTSK | P43235 | 3/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30481196 | 0.89 | LMNA (0.34) | LMNAKMT2AALDH1A1METAP2BCHE | |
| SCHEMBL25702536 | 0.89 | LMNA (0.34) | LMNAKMT2AALDH1A1METAP2BCHE | |
| SCHEMBL30481194 | 0.88 | LMNA (0.31) | LMNAALDH1A1BCHE | |
| SCHEMBL25701985 | 0.88 | LMNA (0.31) | LMNAALDH1A1BCHE | |
| SCHEMBL24418659 | 0.87 | NANP (0.33) | — | |
| SCHEMBL3698732 | 0.87 | NANP (0.33) | — | |
| SCHEMBL12455852 | 0.87 | NANP (0.33) | — | |
| SCHEMBL19249317 | 0.87 | NANP (0.33) | — | |
| SCHEMBL29258956 | 0.87 | NANP (0.33) | — | |
| SCHEMBL30946516 | 0.87 | NANP (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036386-A1 | Heterobifunctional compounds for selectin inhibition | GLYCOMIMETICS, INC (US) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036386-A1 | Heterobifunctional compounds for selectin inhibition | SELE, SELL, BSG | LMNA 2268/4885KMT2A 2610/4885ALDH1A1 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.